Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies

Small-cell lung cancer (SCLC) is an aggressive disease with distinct biological and clinical features. The clinical course of SCLC is generally characterised by initial sensitivity to DNA-damaging therapies, followed by early relapse and broad cross resistance to second line agents. Whilst there has...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamee, Nicholas, da Silva, Ines Pires, Nagrial, Adnan, Gao, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179261/
https://www.ncbi.nlm.nih.gov/pubmed/37175833
http://dx.doi.org/10.3390/ijms24098129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179261/
https://www.ncbi.nlm.nih.gov/pubmed/37175833
http://dx.doi.org/10.3390/ijms24098129

Ejemplares similares